NCT00000569View on ClinicalTrials.gov

Lung Health Study II

PHASE3CompletedINTERVENTIONAL
Enrollment

1,116

Participants

Timeline

Start Date

September 30, 1993

Primary Completion Date

May 31, 1999

Study Completion Date

May 31, 1999

Conditions
Lung DiseasesLung Diseases, ObstructiveChronic Obstructive Pulmonary Disease
Interventions
DRUG

triamcinolone

1200 micrograms of triamcinolone in daily divided doses

OTHER

Placebo

Placebo

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Minnesota

OTHER